Safety and utility of indwelling pleural catheters in lung transplant recipients

Clin Transplant. 2023 Oct;37(10):e15056. doi: 10.1111/ctr.15056. Epub 2023 Jun 24.

Abstract

Introduction: The safety and efficacy of indwelling pleural catheters (IPCs) in lung allograft recipients is under-reported.

Methods: We performed a multicenter, retrospective analysis between 1/1/2010 and 6/1/2022 of consecutive IPCs placed in lung transplant recipients. Outcomes included incidence of infectious and non-infectious complications and rate of auto-pleurodesis.

Results: Seventy-one IPCs placed in 61 lung transplant patients at eight centers were included. The most common indication for IPC placement was recurrent post-operative effusion. IPCs were placed at a median of 59 days (IQR 40-203) post-transplant and remained for 43 days (IQR 25-88). There was a total of eight (11%) complications. Infection occurred in five patients (7%); four had empyema and one had a catheter tract infection. IPCs did not cause death or critical illness in our cohort. Auto-pleurodesis leading to the removal of the IPC occurred in 63 (89%) instances. None of the patients in this cohort required subsequent surgical decortication.

Conclusions: The use of IPCs in lung transplant patients was associated with an infectious complication rate comparable to other populations previously studied. A high rate of auto-pleurodesis was observed. This work suggests that IPCs may be considered for the management of recurrent pleural effusions in lung allograft recipients.

Keywords: complications; indwelling pleural catheters; lung transplantation; pleurodesis.

Publication types

  • Multicenter Study

MeSH terms

  • Catheters, Indwelling / adverse effects
  • Humans
  • Lung
  • Pleural Effusion, Malignant* / etiology
  • Retrospective Studies
  • Transplant Recipients